Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Proc Natl Acad Sci U S A ; 118(20)2021 05 18.
Article in English | MEDLINE | ID: mdl-33972441

ABSTRACT

Neuromodulation of immune function by stimulating the autonomic connections to the spleen has been demonstrated in rodent models. Consequently, neuroimmune modulation has been proposed as a new therapeutic strategy for the treatment of inflammatory conditions. However, demonstration of the translation of these immunomodulatory mechanisms in anatomically and physiologically relevant models is still lacking. Additionally, translational models are required to identify stimulation parameters that can be transferred to clinical applications of bioelectronic medicines. Here, we performed neuroanatomical and functional comparison of the mouse, rat, pig, and human splenic nerve using in vivo and ex vivo preparations. The pig was identified as a more suitable model of the human splenic innervation. Using functional electrophysiology, we developed a clinically relevant marker of splenic nerve engagement through stimulation-dependent reversible reduction in local blood flow. Translation of immunomodulatory mechanisms were then assessed using pig splenocytes and two models of acute inflammation in anesthetized pigs. The pig splenic nerve was shown to locally release noradrenaline upon stimulation, which was able to modulate cytokine production by pig splenocytes. Splenic nerve stimulation was found to promote cardiovascular protection as well as cytokine modulation in a high- and a low-dose lipopolysaccharide model, respectively. Importantly, splenic nerve-induced cytokine modulation was reproduced by stimulating the efferent trunk of the cervical vagus nerve. This work demonstrates that immune responses can be modulated by stimulation of spleen-targeted autonomic nerves in translational species and identifies splenic nerve stimulation parameters and biomarkers that are directly applicable to humans due to anatomical and electrophysiological similarities.


Subject(s)
Immune System/innervation , Immunomodulation/drug effects , Spleen/immunology , Sympathetic Nervous System/immunology , Vagus Nerve/immunology , Animals , Female , Gene Expression , Humans , Immune System/drug effects , Inflammation , Interleukin-6/genetics , Interleukin-6/immunology , Lipopolysaccharides/pharmacology , Mice , Microcirculation/drug effects , Microcirculation/genetics , Microcirculation/immunology , Norepinephrine/pharmacology , Rats , Species Specificity , Spleen/drug effects , Spleen/innervation , Spleen/pathology , Swine , Sympathetic Nervous System/drug effects , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/immunology , Vagus Nerve/drug effects , Vagus Nerve Stimulation/methods
2.
Front Immunol ; 12: 649786, 2021.
Article in English | MEDLINE | ID: mdl-33859641

ABSTRACT

Neuromodulation of the immune system has been proposed as a novel therapeutic strategy for the treatment of inflammatory conditions. We recently demonstrated that stimulation of near-organ autonomic nerves to the spleen can be harnessed to modulate the inflammatory response in an anesthetized pig model. The development of neuromodulation therapy for the clinic requires chronic efficacy and safety testing in a large animal model. This manuscript describes the effects of longitudinal conscious splenic nerve neuromodulation in chronically-implanted pigs. Firstly, clinically-relevant stimulation parameters were refined to efficiently activate the splenic nerve while reducing changes in cardiovascular parameters. Subsequently, pigs were implanted with a circumferential cuff electrode around the splenic neurovascular bundle connected to an implantable pulse generator, using a minimally-invasive laparoscopic procedure. Tolerability of stimulation was demonstrated in freely-behaving pigs using the refined stimulation parameters. Longitudinal stimulation significantly reduced circulating tumor necrosis factor alpha levels induced by systemic endotoxemia. This effect was accompanied by reduced peripheral monocytopenia as well as a lower systemic accumulation of CD16+CD14high pro-inflammatory monocytes. Further, lipid mediator profiling analysis demonstrated an increased concentration of specialized pro-resolving mediators in peripheral plasma of stimulated animals, with a concomitant reduction of pro-inflammatory eicosanoids including prostaglandins. Terminal electrophysiological and physiological measurements and histopathological assessment demonstrated integrity of the splenic nerves up to 70 days post implantation. These chronic translational experiments demonstrate that daily splenic nerve neuromodulation, via implanted electronics and clinically-relevant stimulation parameters, is well tolerated and is able to prime the immune system toward a less inflammatory, pro-resolving phenotype.


Subject(s)
Electric Stimulation Therapy/methods , Endotoxemia/therapy , Neuroimmunomodulation/physiology , Splanchnic Nerves/physiology , Spleen/innervation , Animals , Disease Models, Animal , Electric Stimulation Therapy/instrumentation , Electrodes, Implanted , Endotoxemia/immunology , Female , Inflammation/immunology , Inflammation/therapy , Spleen/immunology , Sus scrofa
3.
Commun Biol ; 3(1): 577, 2020 10 16.
Article in English | MEDLINE | ID: mdl-33067560

ABSTRACT

Neuromodulation is a new therapeutic pathway to treat inflammatory conditions by modulating the electrical signalling pattern of the autonomic connections to the spleen. However, targeting this sub-division of the nervous system presents specific challenges in translating nerve stimulation parameters. Firstly, autonomic nerves are typically embedded non-uniformly among visceral and connective tissues with complex interfacing requirements. Secondly, these nerves contain axons with populations of varying phenotypes leading to complexities for axon engagement and activation. Thirdly, clinical translational of methodologies attained using preclinical animal models are limited due to heterogeneity of the intra- and inter-species comparative anatomy and physiology. Here we demonstrate how this can be accomplished by the use of in silico modelling of target anatomy, and validation of these estimations through ex vivo human tissue electrophysiology studies. Neuroelectrical models are developed to address the challenges in translation of parameters, which provides strong input criteria for device design and dose selection prior to a first-in-human trial.


Subject(s)
Electric Stimulation , Spleen/innervation , Animals , Electric Stimulation/methods , Electric Stimulation Therapy/methods , Electrophysiological Phenomena , Humans , Spleen/anatomy & histology , Spleen/blood supply , Spleen/cytology , Swine
4.
Epilepsia ; 53(3): 425-36, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22221318

ABSTRACT

Retigabine [RTG (international nonproprietary name); ezogabine (EZG; U.S. adopted name)] is a first-in-class antiepileptic drug (AED) that reduces neuronal excitability by enhancing the activity of KCNQ (K(v)7) potassium (K(+)) channels. RTG/EZG has recently been approved by the European Medicines Agency and the U.S. Food and Drug Administration as adjunctive therapy in adults with partial-onset seizures. In this review we discuss the activity that RTG/EZG has demonstrated across a broad spectrum of in vitro/in vivo animal models of seizures, including generalized tonic-clonic, primary generalized (absence), and partial seizures, in addition to the compound's ability to resist and block the occurrence of seizures induced by a range of stimuli across different regions of the brain. The potency of RTG/EZG in models refractory to several conventional AEDs and the work done to assess antiepileptogenesis and neuroprotection are discussed. Studies that have evaluated the central nervous system side effects of RTG/EZG in animals are reviewed in order to compare these effects with adverse events observed in patients with epilepsy. Based on its demonstrated effect in a number of animal epilepsy models, the synergistic and additive activity of RTG/EZG with other AEDs supports its potential use in therapeutic combinations for different seizure types. The distinct mechanism of action of RTG/EZG from those of currently available AEDs, along with its broad preclinical activity, underscores the key role of KCNQ (K(v)7) K(+) channels in neuronal excitability, and further supports the potential efficacy of this unique molecule in the treatment of epilepsy.


Subject(s)
Anticonvulsants/pharmacology , Carbamates/pharmacology , Disease Models, Animal , Epilepsy/drug therapy , Phenylenediamines/pharmacology , Animals , Anticonvulsants/adverse effects , Anticonvulsants/therapeutic use , Carbamates/adverse effects , Carbamates/therapeutic use , Drug Synergism , Epilepsy/classification , Humans , KCNQ Potassium Channels/agonists , KCNQ Potassium Channels/physiology , Neurons/drug effects , Neurons/physiology , Phenylenediamines/adverse effects , Phenylenediamines/therapeutic use , Treatment Outcome
5.
Behav Brain Res ; 218(1): 253-7, 2011 Mar 17.
Article in English | MEDLINE | ID: mdl-21129410

ABSTRACT

Social defeat is an ethologically relevant stress inducing neuroadaptive changes in the mesocorticolimbic dopaminergic system. Three weeks after 10 days of daily defeat salient behaviors and in vivo dopamine (DA) neuron firing were evaluated in mice. Prior defeat induced social avoidance and hyperphagia and increased ventral tegmental area (VTA) DA neuron bursting activity. These data extend previous studies and suggest that increased phasic DA neuron firing in the VTA could be considered amongst the features defining the lasting imprint of social defeat stress.


Subject(s)
Dominance-Subordination , Dopamine/metabolism , Neurons/physiology , Ventral Tegmental Area/physiology , Action Potentials/physiology , Animals , Electrophysiology , Hyperphagia/physiopathology , Mice
6.
Epilepsy Res ; 83(2-3): 103-11, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19041227

ABSTRACT

SUMMARY: The anticonvulsant sodium channel blocker lamotrigine (LTG) increases resting motor threshold (RMT) measured using transcranial magnetic stimulation (TMS) of the motor cortex in humans. However, studies suggest a weak relationship between LTG plasma concentration and increase in RMT. This undermines the possibility to use the technique to investigate the dose-efficacy relationship of lamotrigine or novel sodium channel blocking drugs. In order to investigate this relationship further, we have examined blood and brain concentrations of LTG in parallel with the drugs effects on RMT in a model in which electrical-stimulation is used to activate the motor cortex of propofol-anaesthetised rats. LTG (3-20 mg/kg s.c.) significantly increased RMT (P<0.001). There was a significant (P<0.01) positive correlation between LTG blood and brain concentration and increase in RMT; however correlation-coefficients were low (brain: r(2)=0.26 and blood r(2)=0.25), with evidence for non-responders, similar to human studies. The results show that the variation in RMT response is unlikely to be due to pharmacokinetic differences between subjects, and suggest that biological differences may underpin the variability. Understanding the source of this variability will be an important goal and, assuming some relationship between the effects of LTG on motor pathway excitability and the drugs anticonvulsant efficacy, could lead to a means to identify epilepsy patients that may be more likely to respond to treatment.


Subject(s)
Evoked Potentials, Motor/drug effects , Excitatory Amino Acid Antagonists/pharmacology , Motor Cortex/drug effects , Motor Cortex/physiology , Rest/physiology , Triazines/pharmacology , Analysis of Variance , Animals , Dose-Response Relationship, Drug , Electric Stimulation , Electromyography/methods , Evoked Potentials, Motor/physiology , Excitatory Amino Acid Antagonists/blood , Lamotrigine , Male , Models, Animal , Motor Cortex/metabolism , Rats , Rats, Sprague-Dawley , Regression Analysis , Time Factors , Transcranial Magnetic Stimulation/methods , Triazines/blood
7.
Article in English | MEDLINE | ID: mdl-18958192

ABSTRACT

The basolateral nucleus (BLA) of the amygdala contributes to the consolidation of memories for emotional or stressful events. The nucleus contains a high density of CRF1 receptors that are activated by corticotropin-releasing factor (CRF). Modulation of the excitability of neurons in the BLA by CRF may regulate the immediate response to stressful events and the formation of associated memories. In the present study, CRF was found to increase the amplitude of field potentials recorded in the BLA following excitatory afferent stimulation, in vitro. The increase was mediated by CRF1 receptors, since it could be blocked by the selective, non-peptide antagonists, NBI30775 and NBI35583, but not by the CRF2-selective antagonist, astressin 2B. Furthermore, the CRF2-selective agonist, urocortin II had no effect on field potential amplitude. The increase induced by CRF was long-lasting, could not be reversed by subsequent administration of NBI35583, and required the activation of protein kinase C. This effect of CRF in the BLA may be important for increasing the salience of aversive stimuli under stressful conditions, and for enhancing the consolidation of associated memories. The results provide further justification for studying the efficacy of selective antagonists of the CRF1 receptor to reduce memory formation linked to emotional or traumatic events, and suggest that these compounds might be useful as prophylactic treatments for stress-related illnesses such as post-traumatic stress disorder.

8.
Brain Res ; 1223: 50-8, 2008 Aug 05.
Article in English | MEDLINE | ID: mdl-18599027

ABSTRACT

Endocannabinoids acting through CB(1) receptors are thought to regulate GABAergic and glutamatergic neurotransmission and may modulate long-term potentiation (LTP). High-frequency stimulation (HFS) of the medial perforant path to induce LTP was studied in the dentate gyrus with or without the selective CB(1) receptor antagonist, SR141716A in isoflurane-anaesthetised rats. HFS significantly increased the slope of the field excitatory post-synaptic potential (fEPSP) and the amplitude of the population spike (PS; P<0.001 in each case; n=6). Following administration of SR141716A, HFS no longer increased fEPSP slope, whereas PS amplitude potentiation remained significant (P<0.0001; n=6). Paired-stimuli revealed that HFS significantly reduced inhibition observed at intervals of 10 ms (P<0.01; n=6), and produced a leftward shift of the interval-inhibition curve (P<0.05; n=6). Following administration of SR141716A, HFS no longer reduced inhibition at the 10 ms interval, but a leftward shift in the interval-inhibition curve was still observed (P<0.05, n=6). These results indicate that LTP in the dentate gyrus reduces local circuit inhibition, consistent with a reduction of GABA release and/or duration of the post-synaptic GABA-receptor mediated response. Selective effects of SR141716A on the degree, but not the timecourse, of paired-pulse inhibition suggest that the reduction in GABA release following LTP induction is due to CB(1) activation. Results also suggest that CB(1) receptors contribute to HFS-induced potentiation of the fEPSP, but not to the mechanism underlying potentiation of PS amplitude. We suggest that CB(1) activation during HFS of the medial perforant path increases glutamate release from perforant path synapses, but inhibits release of GABA from local circuit interneurons.


Subject(s)
Cannabinoid Receptor Modulators/metabolism , Dentate Gyrus/metabolism , Feedback/physiology , Neural Inhibition/physiology , Perforant Pathway/metabolism , Piperidines/pharmacology , Pyrazoles/pharmacology , Receptor, Cannabinoid, CB1/metabolism , Animals , Dentate Gyrus/anatomy & histology , Dentate Gyrus/drug effects , Electric Stimulation , Excitatory Postsynaptic Potentials/drug effects , Excitatory Postsynaptic Potentials/physiology , Feedback/drug effects , Glutamic Acid/metabolism , Interneurons/drug effects , Interneurons/metabolism , Long-Term Potentiation/drug effects , Long-Term Potentiation/physiology , Male , Neural Inhibition/drug effects , Perforant Pathway/anatomy & histology , Perforant Pathway/drug effects , Rats , Rats, Sprague-Dawley , Receptor, Cannabinoid, CB1/antagonists & inhibitors , Receptors, GABA/drug effects , Receptors, GABA/metabolism , Rimonabant , Synaptic Transmission/drug effects , Synaptic Transmission/physiology , gamma-Aminobutyric Acid/metabolism
9.
Brain Res ; 1031(1): 141-50, 2005 Jan 07.
Article in English | MEDLINE | ID: mdl-15621024

ABSTRACT

The input from the medial geniculate nucleus of the thalamus (MGN) to the lateral amygdala is known to be important in the regulation of fear and anxiety. Modulation of this pathway may be useful for the treatment of anxiety disorders. We set out to determine whether simple extracellular electrophysiological techniques could be used to study pharmacological modulation of this pathway in vivo. We studied the effects of GABA(B), 5-HT(1), and 5-HT(2) receptor agonists on activity in the lateral amygdala following stimulation of the MGN in isoflurane-anaesthetised rats. Electrical stimulation of the MGN evoked a characteristic biphasic field potential in the lateral amygdala. Baclofen (10 mg kg(-1), iv) inhibited the evoked potential with an effect that was most marked on the positive-going component (80+/-9% inhibition; P<0.05). Baclofen also significantly reduced paired-pulse inhibition of the negative-going component at short interpulse intervals (<200 ms). The 5-HT(1A) receptor ligands, 8-OH-DPAT (60 microg kg(-1), iv) and WAY-100635 (0.5 mg kg(-1), iv) were without effect on evoked responses or paired-pulse relationship. In contrast, the 5-HT(2) receptor agonist, DOI, caused a rapid inhibition of the field potential (to 59.33+/-11.41% of the baseline response; P<0.05). This effect was blocked by ketanserin, either following systemic (0.5 mg kg(-1), iv) or intra-amygdala administration. These results show that GABA(B) and 5-HT(2) receptor agonists can modulate activation of the lateral amygdala following MGN stimulation; furthermore, GABA(B) receptor agonists appear to have a profound effect on local circuit inhibition within the lateral amygdala. The results support the use of in vivo field potential recording within the MGN-lateral amygdala pathway to evaluate this as a possible site of action for novel anxiolytic drugs.


Subject(s)
Amygdala/physiology , Geniculate Bodies/physiology , Receptor, Serotonin, 5-HT1A/physiology , Receptors, GABA-B/physiology , Receptors, Serotonin, 5-HT2/physiology , 8-Hydroxy-2-(di-n-propylamino)tetralin/pharmacology , Amphetamines/pharmacology , Amygdala/cytology , Amygdala/drug effects , Animals , Anxiety/physiopathology , Baclofen/pharmacology , Evoked Potentials/drug effects , Evoked Potentials/physiology , GABA Agonists/pharmacology , Geniculate Bodies/cytology , Ketanserin/pharmacology , Male , Neural Pathways , Piperazines/pharmacology , Pyridines/pharmacology , Rats , Rats, Sprague-Dawley , Serotonin Antagonists/pharmacology , Serotonin Receptor Agonists/pharmacology
10.
Brain Res ; 987(1): 67-75, 2003 Oct 10.
Article in English | MEDLINE | ID: mdl-14499947

ABSTRACT

gamma-Aminobutyric acid (GABA) is a major inhibitory neurotransmitter, which modulates afferent transmission of nociceptive information at different levels of the central nervous system. Plasticity of spinal GABAergic systems may contribute to aberrant nociceptive responses associated with inflammatory and neuropathic pain states. Here potential changes in spinal GABA(B) receptor function in rats with peripheral inflammation and nerve injury, compared to control were investigated. Extracellular recordings of electrically evoked responses of spinal dorsal horn neurones were made in halothane anaesthetised rats. Effects of spinal administration of the GABA(B) receptor agonist baclofen (0.1-10 microg/50 microL) on evoked responses of spinal neurones in control, hindpaw carrageenan inflamed, spinal nerve ligated and sham-operated rats were studied. In all groups of rats, spinal baclofen significantly reduced Abeta-, Adelta- and C-fibre evoked responses of spinal dorsal horn neurones in a dose related manner. Spinal pre-administration of the GABA(B) receptor antagonist, CGP-35348 (30 microg/50 microL) significantly blocked the inhibitory effects of baclofen on evoked neuronal responses in control rats. Estimated ED(50) values for each fibre type within experimental groups were calculated, a significant (P<0.05) difference between the values for Abeta-fibre-evoked and C-fibre mediated post-discharge responses of spinal dorsal horn neurones in spinal nerve ligated rats is reported. This finding may reflect decreased sensitivity of Abeta-fibre-evoked responses to baclofen, as well as an increased sensitivity of post-discharge responses to baclofen in spinal nerve ligated rats. Overall, we report that GABA(B)-receptor control of A- and C-fibre evoked responses of spinal neurones is not profoundly altered in models of inflammatory and neuropathic pain.


Subject(s)
Baclofen/pharmacology , GABA Agonists/pharmacology , Posterior Horn Cells/drug effects , Receptors, GABA-B/metabolism , Spinal Cord/drug effects , Spinal Nerves/injuries , Animals , Carrageenan , Disease Models, Animal , Electric Stimulation , Electrophysiology , GABA Antagonists/pharmacology , GABA-B Receptor Agonists , Inflammation/chemically induced , Male , Organophosphorus Compounds/pharmacology , Posterior Horn Cells/metabolism , Rats , Rats, Sprague-Dawley , Receptors, GABA-B/drug effects , Spinal Cord/metabolism
11.
Brain Res ; 962(1-2): 213-20, 2003 Feb 07.
Article in English | MEDLINE | ID: mdl-12543472

ABSTRACT

Neuropathic pain is a common clinical problem with complex aetiology, mechanisms and symptoms. Alterations in spinal gamma-aminobutyric acid (GABA) receptors may contribute to persistent pain states. The aim of the present study is to investigate potential changes of spinal GABA(A)-receptor function following peripheral nerve injury. Effects of spinal administration of the GABA(A)-receptor agonist muscimol (0.1-30 microg/50 microl) on electrically-evoked responses of spinal neurones in control, spinal nerve ligated and sham operated halothane-anaesthetised rats were studied. Spinal muscimol significantly (10 microg/50 microl) reduced evoked Abeta-, Adelta- and C-fibre responses of spinal neurones in control rats (58+/-22% of control, P<0.05; 3+/-2% of control, P<0.001; and 8+/-7% of control, P<0.001; respectively). Muscimol produced significantly greater inhibition of Adelta- and C-fibre evoked neuronal responses compared to Abeta-fibre evoked neuronal responses in control rats (P<0.001). C-fibre mediated post-discharge responses and the non-potentiated C-fibre evoked responses were significantly inhibited by muscimol in control rats. Inhibitory effects of muscimol (10 microg/50 microl) were blocked by pre-application of spinal bicuculline (10 microg/50 microl). Following either sham surgery, or spinal nerve ligation, spinal muscimol inhibited Abeta-, Adelta- and C-fibre evoked responses of spinal neurones to a similar extent, however significant inhibitory effects on the post-discharge response were not observed in nerve injured rats. Our data demonstrate that GABA(A)-receptor control of Abeta- and Adelta-fibre evoked responses are not altered in nerve injured or sham operated rats, compared to control. However, following nerve injury we report a reduction in GABA(A)-receptor control of C-fibre responses, in particular in relation to post-discharge responses.


Subject(s)
Evoked Potentials/drug effects , Muscimol/pharmacology , Nerve Fibers/physiology , Neurons/physiology , Posterior Horn Cells/physiology , Spinal Cord Injuries/physiopathology , Animals , Bicuculline/pharmacology , GABA Agonists/administration & dosage , GABA Agonists/pharmacology , GABA Antagonists/pharmacology , Injections, Spinal , Male , Muscimol/administration & dosage , Nerve Fibers/drug effects , Neurons/drug effects , Posterior Horn Cells/drug effects , Rats , Rats, Sprague-Dawley , Receptors, GABA/drug effects , Receptors, GABA/physiology , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...